Analystreport

KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lowered by analysts at Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com